Central Retinal Vein Occlusion
Conditions
Brief summary
Recent studies have shown that intravitreal injection of anti-VEGF agent, Lucentis (Ranibizumab) is effective for macular edema associated with central retinal vein occlusion (CRVO). However, there is little information on whether there are any predictive factors of treatment outcome after this treatment. We plan to perform comprehensive functional and imaging tests to determine significant predictive factors.
Detailed description
The purpose of the present study is to investigate predictive factors of treatment outcome after intravitreal injection of Lucentis (Ranibizumab) in eyes with macular edema associated with central retinal vein occlusion (CRVO) using various comprehensive clinical tests including visual filed, spectral-domain optical coherence tomography (SD-OCT), ultra wide-field fluorescein angiography, new flicker electroretinogram (ERG) using skin electrodes. Corrected visual acuity, visual filed, spectral-domain optical coherence tomography (SD-OCT), ultra wide-field fluorescein angiography, and new flicker electroretinogram (ERG) using skin electrodes are performed before and 3, 6, 9, 12 months after the treatment. Predictive factors of treatment outcome are statistically analyzed.
Interventions
DRUGRanibizumab
Sponsors
Mie University
Study design
Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT
Masking
NONE
Eligibility
Sex/Gender
ALL
Age
20 Years to 80 Years
Healthy volunteers
No
Inclusion criteria
* Macular edema associated with central retinal vein occlusion * Best corrected visual acuity \< 20/30 * Central macular thickness \> 300 * Period from symptom onset to treatment \< 12 months
Exclusion criteria
* Any past history of treatment for macular edema (e.g. anti-VEGF injection, steroid, vitrectomy)
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Best-corrected visual acuity | 12 months |
Countries
Japan
Contacts
Primary ContactMineo Kondo, MD, PhD
Outcome results
None listed